Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 28, 2012
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment...
-
Sep 27, 2012Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal...
-
Sep 24, 2012RELIANCE® 4-FRONT™ Lead Designed to Streamline Surgical Procedure for Treatment of Heart Failure and Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable...
-
Sep 19, 2012Company to acquire innovative, minimally invasive technologies for the treatment of coronary chronic total occlusions
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in...
-
Sep 19, 2012New Bronchial Thermoplasty Procedure Codes Effective January 1, 2013
The American Medical Association (AMA) Current Procedural Terminology (CPT®1) Editorial Panel has assigned Category I CPT codes specifically for...
-
Sep 6, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Morgan Stanley Global Healthcare Conference on September 12th in New...
-
Aug 28, 2012
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its PRECISION™ PLUS SPINAL CORD STIMULATOR (SCS) System in patients with...
-
Aug 27, 2012
PRECISION™ PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation PARIS, August 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has...
-
Aug 26, 2012Newly Revised European Society of Cardiology Guidelines Include LAA Closure Devices
European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA)...
-
Jul 27, 2012First European Implants of INGENIO™ MRI Pacemaker with New Image Ready™ Technology Performed This Week
PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...
-
Jul 26, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...
-
Jul 18, 2012Studies Show Innovative Devices Deliver Significant Pain Relief and Reduce Lead Migration in Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...
-
Jul 12, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....
-
Jul 2, 2012Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...
-
Jun 26, 2012
Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and...
-
Jun 14, 2012
Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for...
-
Jun 14, 2012Boston Scientific Announces First Patient Active with LATITUDE™ NXT Remote Patient Management SystemNext-generation wireless remote patient management system enabled for INGENIO(TM) family of pacemakers is now in use in Europe
NATICK, Mass. and PARIS (June 14, 2012) – Boston Scientific Corporation (NYSE: BSX) has initiated use of the LATITUDE NXT Remote Patient Management System with patients in Europe. Dr. Roberto...
-
Jun 8, 2012Adds First and Only Commercially Available Subcutaneous ICD Technology that Offers New Life-Saving Therapy Option to Patients at Risk of Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its...
-
Jun 7, 2012Medical Device Tax Would Stifle Innovation
Boston Scientific (NYSE: BSX) applauds the passage today by the House of Representatives of HR 436, the "Protect Medical Innovation Act." This bill...
-
Jun 6, 2012Event to be webcast live and will include detailed review of Bronchial Thermoplasty opportunity
Boston Scientific Corporation (NYSE: BSX) will hold a review of its Endoscopy business, including its Bronchial Thermoplasty opportunity, on Monday,...
-
Jun 4, 2012PROMUS Element Plus Stent System Offers Physicians the Broadest Array of Everolimus Drug-eluting Stent lengths and diameters in the U.S.
The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX) regulatory approval of 32 mm and 38 mm lengths for...
-
May 31, 2012Devices Projected to Have Nearly Twice the Longevity of Comparable Products
The U.S. Food and Drug Administration (FDA) has approved revised product labeling for the Boston Scientific Corporation (NYSE: BSX) INCEPTA™,...
-
May 29, 2012Indication Provides New Therapeutic Option for Extraction of Difficult-to-Manage Biliary Stones
Boston Scientific Corporation (NYSE: BSX) announces the U.S. Food and Drug Administration has cleared an expanded use indication for the CRE™...
-
May 18, 2012
Boston Scientific Corporation (NYSE: BSX) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week®
-
May 18, 2012Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and...